Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1968 1
1969 1
1971 1
1975 3
1976 2
1978 2
1979 2
1981 1
1982 3
1983 4
1984 4
1985 5
1986 4
1987 8
1988 8
1989 3
1990 11
1991 12
1992 14
1993 10
1994 11
1995 4
1996 10
1997 7
1998 13
1999 14
2000 14
2001 9
2002 16
2003 16
2004 7
2005 13
2006 17
2007 23
2008 15
2009 20
2010 19
2011 22
2012 32
2013 33
2014 28
2015 39
2016 25
2017 38
2018 41
2019 38
2020 35
2021 44
2022 44
2023 42
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Paragangliomas 6"
Page 1
Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension.
Rossi GP, Bisogni V, Rossitto G, Maiolino G, Cesari M, Zhu R, Seccia TM. Rossi GP, et al. High Blood Press Cardiovasc Prev. 2020 Dec;27(6):547-560. doi: 10.1007/s40292-020-00415-9. Epub 2020 Nov 7. High Blood Press Cardiovasc Prev. 2020. PMID: 33159664 Free PMC article. Review.
The aim of this minireview is, therefore, to provide updated concise information on the screening, diagnosis, and management of the most common forms, including primary aldosteronism, renovascular hypertension, pheochromocytoma and paraganglioma, Cushing's syndrome, and ob …
The aim of this minireview is, therefore, to provide updated concise information on the screening, diagnosis, and management of the most com …
Paraganglioma of the Head and Neck: A Review.
Sandow L, Thawani R, Kim MS, Heinrich MC. Sandow L, et al. Endocr Pract. 2023 Feb;29(2):141-147. doi: 10.1016/j.eprac.2022.10.002. Epub 2022 Oct 15. Endocr Pract. 2023. PMID: 36252779 Free PMC article. Review.
RESULTS: Paragangliomas (PGLs) are a group of neuroendocrine tumors that arise in the parasympathetic or sympathetic ganglia. Head and neck PGLs (HNPGLs) comprise 65% to 70% of all PGLs and account for 0.6% of all head and neck cancers. The majority of HNPGLs are be …
RESULTS: Paragangliomas (PGLs) are a group of neuroendocrine tumors that arise in the parasympathetic or sympathetic ganglia. Head an …
Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, Lanza V, Söderkvist P, Stenman A, Larsson C, Svahn F, Chen JL, Marquard J, Fraenkel M, Walter MA, Peczkowska M, Prejbisz A, Jarzab B, Hasse-Lazar K, Petersenn S, Moeller LC, Meyer A, Reisch N, Trupka A, Brase C, Galiano M, Preuss SF, Kwok P, Lendvai N, Berisha G, Makay Ö, Boedeker CC, Weryha G, Racz K, Januszewicz A, Walz MK, Gimm O, Opocher G, Eng C, Neumann HPH; European-American-Asian Pheochromocytoma-Paraganglioma Registry Study Group. Bausch B, et al. JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223. JAMA Oncol. 2017. PMID: 28384794 Free PMC article.
Genetic predictive testing and clinical investigation by imaging from neck to pelvis was offered to mutation-positive registrants and their relatives to clinically characterize the pheochromocytoma/paraganglioma diseases associated with mutations of the 4 new genes. …
Genetic predictive testing and clinical investigation by imaging from neck to pelvis was offered to mutation-positive registrants and …
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M; Phaeochromocytoma Study Group in Japan. Kimura N, et al. Endocr Relat Cancer. 2014 May 6;21(3):405-14. doi: 10.1530/ERC-13-0494. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24521857
Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, histopathological criteria to discriminate malignant from benign tumours have not been established; therefore, reliable histopathological ma …
Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, …
Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.
Buitenwerf E, Osinga TE, Timmers HJLM, Lenders JWM, Feelders RA, Eekhoff EMW, Haak HR, Corssmit EPM, Bisschop PHLT, Valk GD, Veldman RG, Dullaart RPF, Links TP, Voogd MF, Wietasch GJKG, Kerstens MN. Buitenwerf E, et al. J Clin Endocrinol Metab. 2020 Jul 1;105(7):2381-91. doi: 10.1210/clinem/dgz188. J Clin Endocrinol Metab. 2020. PMID: 31714582 Free PMC article. Clinical Trial.
Secondary efficacy endpoint was the value on a hemodynamic instability score. RESULTS: Median cumulative time outside blood pressure targets was 11.1% (interquartile range [IQR]: 4.3-20.6] in the phenoxybenzamine group compared to 12.2% (5.3-20.2)] in the doxazosin …
Secondary efficacy endpoint was the value on a hemodynamic instability score. RESULTS: Median cumulative time outside blood pressure …
Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, LiVolsi V, Krumeich L, Fraker DL, Nathanson KL, Cohen DL, Fishbein L. Wachtel H, et al. J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4661-70. doi: 10.1210/clinem/dgaa608. J Clin Endocrinol Metab. 2020. PMID: 32877928 Free PMC article.
PURPOSE: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP) are scoring systems to predict metastatic potential in pheochromocytomas (PCC) and paraganglio …
PURPOSE: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Par …
Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi N, Corti F, Torchio M, Niger M, Antista M, Pagani F, Beninato T, Pulice I, Rossi RE, Coppa J, Cascella T, Giacomelli L, Di Bartolomeo M, Milione M, de Braud F, Pusceddu S. Prinzi N, et al. Tumori. 2022 Dec;108(6):526-540. doi: 10.1177/03008916221078621. Epub 2022 May 20. Tumori. 2022. PMID: 35593402 Review.
Pheochromocytomas and paragangliomas (PPGLs) can metastasize in approximately 15-20% of cases. ...In patients with high MIBG uptake and positive PETGa-68, radiometabolic treatment may be considered. The efficacy of sunitinib has been shown in observational studies, …
Pheochromocytomas and paragangliomas (PPGLs) can metastasize in approximately 15-20% of cases. ...In patients with high MIBG uptake a …
Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD.
Andrews KA, Ascher DB, Pires DEV, Barnes DR, Vialard L, Casey RT, Bradshaw N, Adlard J, Aylwin S, Brennan P, Brewer C, Cole T, Cook JA, Davidson R, Donaldson A, Fryer A, Greenhalgh L, Hodgson SV, Irving R, Lalloo F, McConachie M, McConnell VPM, Morrison PJ, Murday V, Park SM, Simpson HL, Snape K, Stewart S, Tomkins SE, Wallis Y, Izatt L, Goudie D, Lindsay RS, Perry CG, Woodward ER, Antoniou AC, Maher ER. Andrews KA, et al. J Med Genet. 2018 Jun;55(6):384-394. doi: 10.1136/jmedgenet-2017-105127. Epub 2018 Jan 31. J Med Genet. 2018. PMID: 29386252 Free PMC article.
BACKGROUND: Germline pathogenic variants in SDHB/SDHC/SDHD are the most frequent causes of inherited phaeochromocytomas/paragangliomas. Insufficient information regarding penetrance and phenotypic variability hinders optimum management of mutation carriers. ...Tumour risks …
BACKGROUND: Germline pathogenic variants in SDHB/SDHC/SDHD are the most frequent causes of inherited phaeochromocytomas/paragangliomas …
Orbital Paraganglioma.
Zhu B, Yan J. Zhu B, et al. J Craniofac Surg. 2019 Sep;30(6):e503-e506. doi: 10.1097/SCS.0000000000005408. J Craniofac Surg. 2019. PMID: 30896513
BACKGROUND: Paragangliomas are groups of neuroendocrine neoplasms originating from neural crest cells throughout the body, but are rarely observed within the orbit. ...After a second surgery and local radiotherapy, there were no signs of the recurrence as assessed a …
BACKGROUND: Paragangliomas are groups of neuroendocrine neoplasms originating from neural crest cells throughout the body, but are ra …
Metastatic pheochromocytoma and paraganglioma.
Angelousi A, Kassi E, Zografos G, Kaltsas G. Angelousi A, et al. Eur J Clin Invest. 2015 Sep;45(9):986-97. doi: 10.1111/eci.12495. Eur J Clin Invest. 2015. PMID: 26183460 Review.
BACKGROUND: Metastatic pheochromocytomas (PCs) and paragangliomas (PGLs) are rare neuroendocrine tumours with a strong genetic background. DESIGN: We searched the PubMed database through February 2015 to identify studies characterizing metastatic PCs/PGLs as well as curren …
BACKGROUND: Metastatic pheochromocytomas (PCs) and paragangliomas (PGLs) are rare neuroendocrine tumours with a strong genetic backgr …
723 results